Champions TumorGraft® PDX Models Used in Clinical and Research Settings Featured at AACR Annual Meeting
Hackensack, NJ – April 18, 2015 – Champions Oncology, Inc. (OTC : CSBR) a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the presentation of data from applications of Champions TumorGraft® PDX models in clinical and research settings at the American Association for Clinical Research (AACR) Annual Meeting 2015.
The presentations will be delivered by addressing delegates as well as during general poster sessions at the Philadelphia Convention Center between Saturday, April 18 and Wednesday, April 22.
- Champions Oncology Poster – A Patient-centric Repository of PDX Models for Translational Oncology Research -Tue, Apr 21, 8:00 AM – 12:00 PM Exhibit Hall, Poster Section 15, Board 1
- Champions Oncology Poster – A Humanized Mouse Model for Translational Assessment of Targeted Immune Checkpoint Blockade -Wed, Apr 22, 8:00 AM – 12:00 PM Exhibit Hall, Poster Section 11, Board 23
- Presentation, Neal Goodwin, PhD, Vice President, Corporate Research & Development – Translating Insights from Mouse Cancer Models to Therapeutic Targeting -Sat, Apr 18, 3:15 – 5:15 PM Room 114
- Presentation, Neal Goodwin, PhD, Vice President, Corporate Research & Development – Opportunities and Challenges in the Use of Animal Models for Cancer Target Validation and Drug Development -Mon, Apr 20, 5:00 – 6:30 PM Terrace Ballroom IV (400 Level)
- Presentation, David Sidransky, MD, Chairman – Avatar Mouse Models for Personalized Cancer Treatment -Tue, Apr 21, 5:00 – 6:30 PM Room 103
- Poster featuring Champions TumorGrafts – Mouse PDX Trial Suggests Combination Efficacy of Raf and EGFR Inhibition in Colorectal Cancer with BRaf or KRas Mutation -Sun, Apr 19, 1:00 – 5:00 PM Exhibit Hall, Late Breaking Poster Section 39
- Poster featuring Champions TumorGrafts – Medi3622, a Monoclonal Antibody to ADAM17, Inhibits Tumor Growth by Inhibiting EGFR- and non-EGFR-Mediated Pathways -Sun, Apr 19, 1:00 – 5:00 PM Exhibit Hall, Poster Section 2, Board 1